AbbVie Inc. Files 8-K on Financials and Senior Notes
Ticker: ABBV · Form: 8-K · Filed: 2024-10-30T00:00:00.000Z
Sentiment: neutral
Topics: financials, debt, sec-filing
Related Tickers: ABBV
TL;DR
AbbVie dropped an 8-K on Oct 30th detailing its financials and a bunch of senior notes due between 2027-2031.
AI Summary
On October 30, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior notes due in 2027, 2028, 2029, and 2031, with interest rates ranging from 0.750% to 2.625%. This report serves as an update on the company's financial standing and debt instruments.
Why It Matters
This filing provides investors with an update on AbbVie's financial health and its outstanding debt obligations, which are crucial for assessing the company's stability and future investment potential.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) that provides updates on operations and existing debt instruments, not indicating new or significant risks.
Key Numbers
- 0.750% — Senior Notes Interest Rate (Lowest interest rate on notes due 2027)
- 2.625% — Senior Notes Interest Rate (Highest interest rate on notes due 2028)
- 2027-2031 — Senior Notes Maturity Dates (Range of maturity dates for outstanding senior notes)
Key Players & Entities
- AbbVie Inc. (company) — Registrant
- October 30, 2024 (date) — Date of earliest event reported
- 0.750% (dollar_amount) — Interest rate on Senior Notes due 2027
- 2.625% (dollar_amount) — Interest rate on Senior Notes due 2028
- 2027 (date) — Maturity year for Senior Notes
- 2031 (date) — Maturity year for Senior Notes
FAQ
What is the purpose of this 8-K filing for AbbVie Inc.?
The 8-K filing on October 30, 2024, is to report on AbbVie Inc.'s Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
What specific financial instruments are mentioned in the filing?
The filing mentions several series of Senior Notes, including those due in 2027, 2028, 2029, and 2031, with varying interest rates.
What are the interest rates for the mentioned Senior Notes?
The interest rates range from 0.750% for notes due 2027, to 2.125% and 2.625% for notes due 2028, 2.125% for notes due 2029, and 1.250% for notes due 2031.
When was this report filed?
This 8-K report was filed as of October 30, 2024.
What is AbbVie Inc.'s fiscal year end?
AbbVie Inc.'s fiscal year ends on December 31.
From the Filing
0001551152-24-000036.txt : 20241030 0001551152-24-000036.hdr.sgml : 20241030 20241030074314 ACCESSION NUMBER: 0001551152-24-000036 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241030 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241030 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 241407472 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20241030.htm 8-K abbv-20241030 0001551152 false 0001551152 2024-10-30 2024-10-30 0001551152 exch:XNYS us-gaap:CommonStockMember 2024-10-30 2024-10-30 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-10-30 2024-10-30 0001551152 exch:XNYS abbv:Sec0.750SeniorNotesDue2027Member 2024-10-30 2024-10-30 0001551152 exch:XNYS abbv:Sec2.125SeniorNotesdue2028Member 2024-10-30 2024-10-30 0001551152 exch:XNYS abbv:Sec2625SeniorNotesDue2028Member 2024-10-30 2024-10-30 0001551152 exch:XNYS abbv:Sec2125SeniorNotesDue2029Member 2024-10-30 2024-10-30 0001551152 exch:XNYS abbv:Sec1.250SeniorNotesdue2031Member 2024-10-30 2024-10-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 30, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐                       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027 ABBV27 New York Stock Exchange 2.125% Senior Notes due 2028 ABBV28 New York Stock Exchange 2.625% Senior